Oramed Pharmaceuticals Inc (ORMP)

7.72
0.03 0.39
NASDAQ : Health Care
Prev Close 7.75
Open 7.78
Day Low/High 7.65 / 7.81
52 Wk Low/High 4.15 / 10.74
Volume 23.67K
Avg Volume 54.80K
Exchange NASDAQ
Shares Outstanding 13.14M
Market Cap 102.86M
EPS -0.70
P/E Ratio 11.35
Div & Yield N.A. (N.A)

Latest News

Oramed Announces $6.5 Million Milestone Payment From HTIT

Oramed Announces $6.5 Million Milestone Payment From HTIT

Payment comes in wake of positive topline phase IIB results

Oramed Announces Positive Top-Line Results From Phase IIb Oral Insulin Study

Oramed Announces Positive Top-Line Results From Phase IIb Oral Insulin Study

All Primary Safety and Efficacy Endpoints Were Met; Conference Call Today at 11:00 am EDT

Oramed Receives Patent Term Adjustment Extending The Term Of Its U.S. Patent

Oramed Receives Patent Term Adjustment Extending The Term Of Its U.S. Patent

Patent addresses platform technology for oral insulin capsule ORMD-0801

Oramed Completes Phase IIb Oral Insulin Study

Oramed Completes Phase IIb Oral Insulin Study

Top-Line Data to be Released This Quarter

Oramed Pharmaceuticals (ORMP) Stock Surges on $50 Million Chinese Licensing Deal

Oramed Pharmaceuticals (ORMP) Stock Surges on $50 Million Chinese Licensing Deal

Oramed Pharmaceuticals (ORMP) stock is rising on heavy volume trading on Monday after the clinical-stage pharmaceutical company announced a $50 million licensing deal in China.

Oramed Signs Up To $50 Million Licensing And Investment Agreements For Oral Insulin Capsule In China

Oramed Signs Up To $50 Million Licensing And Investment Agreements For Oral Insulin Capsule In China

Receiving up to $38,000,000 + royalties for licensing deal and $12,000,000 for equity investment at $10.39 per share

Oramed Completes Randomization Of Over 50% Of Patients In Phase IIb Oral Insulin Study

Oramed Completes Randomization Of Over 50% Of Patients In Phase IIb Oral Insulin Study

180 Patients Expected to be Enrolled in Study

3 Stocks Under $10 to Trade for Breakouts

3 Stocks Under $10 to Trade for Breakouts

These under-$10 stocks are within range of triggering breakout trades.

3 Stocks Under $10 Triggering Breakout Trades

3 Stocks Under $10 Triggering Breakout Trades

These under-$10 stocks are within range of triggering big breakout trades.

Oramed Enrolls First Patient In Its Phase IIb Oral Insulin Study

Oramed Enrolls First Patient In Its Phase IIb Oral Insulin Study

Company's largest study to date with over 30 clinical sites in the United States to participate

Oramed Submits Protocol To U.S. FDA For Its Phase IIb Oral Insulin Study

Oramed Submits Protocol To U.S. FDA For Its Phase IIb Oral Insulin Study

Company's largest study to date with over 30 clinical sites in the U.S. to participate

Oramed Submits Protocol To U.S. FDA For Its Phase IIb Oral Insulin Study

Oramed Submits Protocol To U.S. FDA For Its Phase IIb Oral Insulin Study

Company's largest study to date with over 30 clinical sites in the U.S. to participate

Oramed To Present At Upcoming Conferences

Oramed To Present At Upcoming Conferences

Presentations Scheduled at Oppenheimer 16th Annual Israeli Conference and IATI Biomed 2015 in May